U19AI181930

Paramyxoviridae and Bunyavirales vaccines and antibodies center (PABVAX) - Project summary/abstract - Overall emerging and reemerging pathogenic RNA viruses represent continuous infectious disease and pandemic threats to public health.

Among the many groups of these types of pathogens are viral zoonoses within the family Paramyxoviridae and order Bunyavirales.

The Bunyavirales is composed of several viral families known to contain several high priority human pathogens.

Notably, Arenaviridae and Nairoviridae families contain viruses which cause severe hemorrhagic diseases in humans worldwide with associated high morbidity and mortality.

A host of arenaviruses viruses, including Lassa, Machupo, Lujo, and Chapare viruses and the Nairovirus Crimean-Congo hemorrhagic fever virus are also included among the World Health Organization’s (WHO) list of priority pathogens.

The zoonotic henipaviruses (HNVs) including Nipah virus (NIV) and Hendra virus (HEV), in the Paramyxoviridae family are also on the WHO priority pathogens.

These HNVs have a uniquely broad host tropism, causing an often fatal respiratory and/or neurological disease, and are significant biothreats to humans and livestock in Southeast Asia and Australia.

All these RNA virus threats to global public health are heightened due to the absence of approved vaccines or therapeutics.

There is a clear unmet need for countermeasures to address the threat of natural outbreaks, epidemics, or deliberate release.

The Paramyxoviridae and Bunyavirales vaccines and antibodies center (PABVAX) is a well-integrated consortium conducting a set of discovery and translational research programs composed of a data management core, 3 scientific cores, and 5 research projects (RPs).

The synergistic activities of center partners will be focused on: developing, testing, and translating prototype subunit vaccines employing a novel adjuvanted dissolvable, microneedle patch (MNP) vaccine platform; developing new virus and animal model tools; and developing and testing monoclonal antibody and nanobody prototypes to foster pandemic preparedness.

The level of team experience in both vaccines and antibody countermeasure advancements among the RPs is a major strength and advantage of this center.

The PABVAX center’s overall objective is to elucidate key principles for vaccine and antibody-based countermeasures in developing prototype candidates against a selection of these viruses.

In the out years of the effort, the center will exploit these learned key principles in a “plug and play” approach against related viruses.

University Of Texas Medical Branch At Galveston

TO ASSIST PUBLIC AND PRIVATE NONPROFIT INSTITUTIONS AND INDIVIDUALS TO ESTABLISH, EXPAND AND IMPROVE BIOMEDICAL RESEARCH AND RESEARCH TRAINING IN INFECTIOUS DISEASES AND RELATED AREAS, TO CONDUCT DEVELOPMENTAL RESEARCH, TO PRODUCE AND TEST RESEARCH MATERIALS. TO ASSIST PUBLIC, PRIVATE AND COMMERCIAL INSTITUTIONS TO CONDUCT DEVELOPMENTAL RESEARCH, TO PRODUCE AND TEST RESEARCH MATERIALS, TO PROVIDE RESEARCH SERVICES AS REQUIRED BY THE AGENCY FOR PROGRAMS IN INFECTIOUS DISEASES, AND CONTROLLING DISEASE CAUSED BY INFECTIOUS OR PARASITIC AGENTS, ALLERGIC AND IMMUNOLOGIC DISEASES AND RELATED AREAS. PROJECTS RANGE FROM STUDIES OF MICROBIAL PHYSIOLOGY AND ANTIGENIC STRUCTURE TO COLLABORATIVE TRIALS OF EXPERIMENTAL DRUGS AND VACCINES, MECHANISMS OF RESISTANCE TO ANTIBIOTICS AS WELL AS RESEARCH DEALING WITH EPIDEMIOLOGICAL OBSERVATIONS IN HOSPITALIZED PATIENTS OR COMMUNITY POPULATIONS AND PROGRESS IN ALLERGIC AND IMMUNOLOGIC DISEASES. BECAUSE OF THIS DUAL FOCUS, THE PROGRAM ENCOMPASSES BOTH BASIC RESEARCH AND CLINICAL RESEARCH. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM EXPANDS AND IMPROVES PRIVATE SECTOR PARTICIPATION IN BIOMEDICAL RESEARCH. THE SBIR PROGRAM INTENDS TO INCREASE AND FACILITATE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. THE SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM STIMULATES AND FOSTERS SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. RESEARCH CAREER DEVELOPMENT AWARDS SUPPORT THE DEVELOPMENT OF SCIENTISTS DURING THE FORMATIVE STAGES OF THEIR CAREERS. INDIVIDUAL NATIONAL RESEARCH SERVICE AWARDS (NRSAS) ARE MADE DIRECTLY TO APPROVE APPLICANTS FOR RESEARCH TRAINING IN SPECIFIED BIOMEDICAL SHORTAGE AREAS. IN ADDITION, INSTITUTIONAL NATIONAL RESEARCH SERVICE AWARDS ARE MADE TO ENABLE INSTITUTIONS TO SELECT AND MAKE AWARDS TO INDIVIDUALS TO RECEIVE TRAINING UNDER THE AEGIS OF THEIR INSTITUTIONAL PROGRAM.

93.855 - Allergy and Infectious Diseases Research

National Institute of Allergy and Infectious Diseases (NIAID) [HHS - NIH]

Galveston, Texas 775555302 United States

Single Zip Code

Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Centers for Bunyavirales, Paramyxoviridae and Picornaviridae (U19 Clinical Trial Not Allowed) (RFA-AI-23-020)